- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01199198
Tolvaptan in Hyponatremic Cancer Patients
Randomized Placebo-Controlled Trial of Tolvaptan in Hyponatremic Patients With Cancer
Study Overview
Detailed Description
The Study Drug:
Tolvaptan is designed to help raise salt levels in your blood by removing extra body water as urine.
Study Groups:
If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to 1 of 2 groups. You will have an equal chance of being assigned to either group:
- If you are in Group 1, you will take tolvaptan and receive standard of care
- If you are in Group 2, you will take a placebo and receive the standard of care for patients with hyponatremia. A placebo is a tablet that looks like the study drug but has no active ingredients.
You will not know which group you are assigned. However, if needed for your safety, you will be able to find out what you are receiving at any time.
Study Drug Administration:
You will take tolvaptan or the placebo 1 time every day by mouth for 14 days.
If you are receiving the placebo, you will also receive the standard of care for hyponatremia. Examples of the standard of care include limiting your water and fluid intake, or giving you salt tablets and other drugs such as diuretics. Your doctor will describe these in more detail.
You will be given a drug diary to record when you take the study drug/placebo. You will return any unused drug/placebo at the end of 14 days.
You should avoid grapefruit and grapefruit juice while you are taking tolvaptan.
Study Visits:
At every visit, you will be asked if you have had any side effects.
On Days 1, 2, and 3:
- Blood (about 1 teaspoon) will be drawn for routine tests. On Day 1, this sample will be drawn 2 times.
- Your weight and vital signs will be measured.
- The study staff will record how much fluid you are drinking and how much you are urinating.
- You will be asked about any drugs that you may be taking.
- If the doctor thinks it is needed, you will have a physical exam.
On Day 7:
- Your medical history will be reviewed and updated.
- You will be asked about any drugs that you may be taking.
- Blood (about 1 teaspoon) will be drawn for routine tests and tests to measure how concentrated your blood results are.
- Your weight and vital signs will be measured.
On Day 14:
- Your medical history will be reviewed and updated.
- Your weight and vital signs will be measured.
- Blood (about 1 teaspoon) and urine will be collected for routine tests and tests to measure how concentrated your blood and urine are.
- The study staff will record how much fluid you are drinking and how much you are urinating.
- You will be asked about any drugs that you may be taking.
- You will complete the MMSE.
If the doctor thinks it is needed, you will have a physical exam.
Length of Study:
You will take the study drug/placebo for 14 days. You will be taken off study if you have intolerable side effects, if the disease gets worse, or if the study doctor thinks it is in your best interest.
Your participation on the study will be over once you have completed the end-of-study visit.
End-of-Study- Day 30 Follow-up Visit:
At 30 days after the last dose of study drug (or placebo), you will have an end-of-study visit in clinic or by telephone. At this visit, the following tests and procedures will be performed.
- Your medical history will be reviewed and updated.
- Blood (about 1 teaspoon) will be drawn for routine tests and tests to measure how concentrated your blood results are.
- You will be asked about any side effects that you may be having and any drugs that you may be taking.
- The study staff will record how much fluid you are drinking and how much you are urinating.
- If the doctor thinks it is needed, you will have a physical exam.
This is an investigational study. Tolvaptan is FDA approved and commercially available to treat hyponatremia (low levels of salt [sodium] in the blood due to too much body water). Its use in patients with cancer who have hyponatremia is investigational.
Up to 170 patients will take part in this study. All will be enrolled at MD Anderson.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- UT MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Euvolemic or hypervolemic (patients with heart or liver failure) with cancer admitted to MD Anderson Cancer Center for any reasons with serum sodium between 125 and 130 mEq/L (both inclusive)
- Patients must be greater than or equal to 18 years of age
- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 at baseline.
- Women of childbearing potential must use a medically accepted method of contraception and to continue use of this method for the duration of the study and for 30 days after study participation. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method. Men must practice abstinence or use a barrier method of birth control, and must agree to continue use for the duration of the study and for 30 days after study participation.
- Subjects must be able to comply with scheduled visits and follow-ups.
- Informed consent must be signed
Exclusion Criteria:
- History of hypersensitivity to tolvaptan
- Patients admitted to the critical care unit.
- Patients with renal failure(creatinine clearance less than 25 ml/min)
- Patients with a life expectancy less than 3 months
- Patients with volume depletion, BP < 100/60 or urinary sodium <20 meq/L.
- Patients who are not able to swallow or cannot take medication through feeding tubes
- Patients with diuretic-induced hyponatremia.
- Patients with spurious hyponatremia
- Patients with hyponatremia related to psychogenic polydypsia, head trauma, post operative conditions, uncontrolled hypothyroidism or cortisol insufficiency or any hyponatremia associated with the use of medication that can be safely withdrawn.
- The use of alcohol while participating in the study
- Currently taking demeclocycline, lithium, benzazepine derivatives, ketoconazole, grapefruit, grapefruit juice and receiving strong CYP3A inhibitors such as clarithromycin, fluconazole, voriconazole, posaconazole, itraconazole, ritonavir, indinavir, nelfinavir, saquinavir, nefazodone, and telithromycin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tolvaptan Group
Tolvaptan Group: Starting dose 15 mg by mouth once a day for 14 days.
|
Starting dose 15 mg by mouth once a day for 14 days.
Other Names:
|
Placebo Comparator: Placebo Group
Placebo Group: Placebo by mouth once a day for 14 days.
|
Placebo by mouth once a day for 14 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participants Whose Serum Sodium Concentration Corrected to at Least 135 mEq/L on Day 14
Time Frame: 14 days
|
Compare proportion of hyponatremia cancer patients with a normalized serum sodium concentration at day 14 between those treated with Tolvaptan and those treated with a placebo (standard of care).
Proportion of participants whose serum sodium concentration is corrected to at least 136 mEq/Lon day14.
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Length of Stay in Hospital
Time Frame: From administration of treatment to time of discharge
|
From administration of treatment to time of discharge
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Abdulla K. Salahudeen, MD, UT MD Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009-0862
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancers
-
Agenus Inc.CompletedAdvanced Solid Cancers | Advanced Solid Cancers Refractory to PD-1United States
-
M.D. Anderson Cancer CenterEuropean CommissionCompletedAdvanced CancersUnited States, Spain, France, Israel
-
Aeglea BiotherapeuticsCompletedAdvanced CancersUnited States
-
M.D. Anderson Cancer CenterFoundation MedicineCompleted
-
M.D. Anderson Cancer CenterCompleted
-
M.D. Anderson Cancer CenterSabinsa CorporationWithdrawnAdvanced Cancers
-
M.D. Anderson Cancer CenterTerminatedAdvanced CancersUnited States
-
M.D. Anderson Cancer CenterCompleted
-
M.D. Anderson Cancer CenterTerminated
-
M.D. Anderson Cancer CenterYukiguni Maitake Company Ltd.Terminated
Clinical Trials on Tolvaptan
-
Otsuka Pharmaceutical Development & Commercialization...RecruitingAutosomal Recessive Polycystic Kidney (ARPKD)United States, United Kingdom, Belgium, Poland, France, Germany, Italy
-
Regional Hospital HolstebroAarhus University HospitalCompleted
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
NYU Langone HealthWithdrawnSIADH | Cerebral Hyponatremia | Cerebral Salt-wasting Syndrome | Reset Hypothalamic OsmostatUnited States
-
Eli Lilly and CompanyActive, not recruitingPlaque Psoriasis | Psoriatic ArthritisIndia
-
Otsuka Pharmaceutical Co., Ltd.CompletedPolycystic Kidney, Autosomal DominantJapan
-
Otsuka Pharmaceutical Co., Ltd.CompletedAutosomal Dominant Polycystic Kidney Disease (ADPKD)Japan
-
University of North Carolina, Chapel HillOtsuka America PharmaceuticalCompletedHeart Diseases | Cardiovascular Diseases | Heart FailureUnited States
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka Pharmaceutical Co., Ltd.CompletedInappropriate ADH Syndrome | Water Intoxication | Hyponatremias | Water-Electrolyte ImbalancesUnited States